MedPath

Safety and Performance study in Diabetics with the Limus Eluting Orsiro Stent System in daily clinical practice

Phase 4
Conditions
Health Condition 1: null- Diabetic Patients requiring Vascular Intervention with Drug Eluting Stent
Registration Number
CTRI/2013/09/003967
Lead Sponsor
BIOTRONIK Asia Pacific Pte Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
880
Inclusion Criteria

Diabetes Mellitus:

Known Diabetic on Pharmacological treatment.

ACS NSTEMI with documented Hb A1c >7%, even if not on Pharmacological treatment for diabetes.

Subject is >= 18 years of age

Patient has Symptomatic coronary artery disease

Target lesion must be a de novo lesion located in a native coronary artery with reference vessel

diameter >=2.25 mm & <=4.00 mm, lesion length <=40 mm by visual estimate

Patient should be receiving upto 3 stents and upto 2 stents per artery.

Target lesion must be in a major coronary artery

or branch with visually estimated stenosis >=50%

& <100% with TIMI flow>=1.

Subject provides signed informed consent for data release Subject is geographically stable and willing to comply with protocol required follow ups

Exclusion Criteria

Pregnant and/or breast-feeding females who

intend to become pregnant during the period of

the registry

Untreatable intolerance to aspirin, clopidogrel,

ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless

steel, Sirolimus or contrast media

Planned surgery within 6 months of PCI unless

dual antiplatelet therapy will be maintained

Currently participating in another study and

primary endpoint is not reached yet.

if the subject has a high probability that a

procedure other than predilatation, stent

implantation and post dilatation will be required at time of index procedure for treatment of target

vessel (e.g. atherectomy, cutting balloon or

brachytherapy).

Patients admitted for treatment of Diabetic

ketoacedosis >= 2 times in the past Six months

(Brittle Diabetics).

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath